Scarica l'app Stockscreener
1.51
0.00%
0.03
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics director buys $6.7k in company stock - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares - Investing.com India
Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com Australia
Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com Canada
Plus Therapeutics director buys $6.7k in company stock - Investing.com
Petersen Greg buys $16,875 worth of Plus Therapeutics shares - Investing.com
Petersen Greg buys $16,875 worth of Plus Therapeutics shares By Investing.com - Investing.com UK
Plus Therapeutics CEO buys $9.8k in company stock - Investing.com
Plus Therapeutics faces Nasdaq delisting over equity shortfall By Investing.com - Investing.com Australia
Plus Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com India
Plus Therapeutics faces Nasdaq delisting over equity shortfall - Investing.com
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $20.00 at Ascendiant Capital Markets - Defense World
Plus Therapeutics stock sees reduced target after softer-than-expected Q2 results - Investing.com
Analyzing Plus Therapeutics (NASDAQ:PSTV) and Endologix (OTCMKTS:ELGXQ) - Defense World
HC Wainwright Comments on Galectin Therapeutics Inc.’s Q1 2025 Earnings (NASDAQ:GALT) - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Expected to Post FY2024 Earnings of ($3.90) Per Share - Defense World
Plus Therapeutics Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus Therapeutics Shareholders Elect Board, Approve Proposals - Investing.com India
Plus Therapeutics Shareholders Elect Board, Approve Proposals By Investing.com - Investing.com Australia
FDA Approves Durvalumab for Resectable NSCLC - OBR Oncology
Plus Therapeutics Shareholders Elect Board, Approve Proposals By Investing.com - Investing.com Canada
Plus Therapeutics Shareholders Elect Board, Approve Proposals - Investing.com
Plus Therapeutics Shareholders Elect Board, Approve Proposals By Investing.com - Investing.com UK
Earnings call: Plus Therapeutics reports clinical progress and financials By Investing.com - Investing.com Australia
Earnings call: Plus Therapeutics reports clinical progress and financials - Investing.com India
Earnings call: Plus Therapeutics reports clinical progress and financials - Investing.com
Earnings call: Plus Therapeutics reports clinical progress and financials By Investing.com - Investing.com UK
Plus Therapeutics Inc (PSTV) Q2 2024 Earnings Call Transcript Hi - GuruFocus.com
Plus: Q2 Earnings Snapshot - San Antonio Express-News
Lykos Therapeutics cuts 75% of staff after FDA rejects MDMA-assisted therapy - STAT
Plus: Q2 Earnings Snapshot - Thehour.com
Plus: Q2 Earnings Snapshot - New Haven Register
Plus: Q2 Earnings Snapshot - San Francisco Chronicle
Plus: Q2 Earnings Snapshot - CTPost
Plus: Q2 Earnings Snapshot - Weatherford Democrat
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Yahoo Finance
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - StockTitan
Plus Therapeutics Q2 24 Earnings Conference Call At 5:00 PM ET - Nasdaq
PSTVPlus Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Plus Therapeutics reports progress in CNS cancer diagnostics - Investing.com
Plus Therapeutics reports progress in CNS cancer diagnostics - Investing.com India
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference - GlobeNewswire
Plus Therapeutics reports progress in CNS cancer diagnostics By Investing.com - Investing.com UK
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference - ForexTV.com
Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference - StockTitan
Plus Therapeutics reports progress in CNS cancer trial - Investing.com
Rhenium Obisbemeda Demonstrates Safety and Feasibility in Leptomeningeal Metastases - OncLive
Plus Therapeutics reports progress in CNS cancer trial By Investing.com - Investing.com UK
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference - ForexTV.com
Plus Therapeutics Presents Positive Interim ReSPECT-LM - GlobeNewswire
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal - The Bakersfield Californian
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference - StockTitan
Plus Therapeutics (PSTV) to Release Quarterly Earnings on Wednesday - Defense World
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 - ForexTV.com
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 - GlobeNewswire
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 - StockTitan
FDA Awards Orphan Drug Designation to Avutometinib Plus Defactinib in Pancreatic Cancer - OncLive
FDA Decision Tracker: J&J Scores New Approval for Multiple Myeloma Therapy - BioSpace
IMNN-01 Plus Perioperative Chemo Improves OS in Newly Diagnosed, Advanced Ovarian Cancer - OncLive
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
IDH Inhibitor Market to Exhibit Significant Growth Rate During the Study Period (2020–2034) | DelveInsight - India Shorts
1.10%
1.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):